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CRAF R391W is a melanoma driver 
oncogene
Mohammad Atefi1,*, Bjoern Titz2,3,*, Jennifer Tsoi2,3, Earl Avramis1, Allison Le2,3, Charles Ng4, 
Anastasia Lomova2,3, Amanda Lassen1, Michael Friedman2,3, Bartosz Chmielowski1,4, 
Antoni Ribas1,2,5,6 & Thomas G. Graeber2,3,4,7
Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or 
GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas 
are not known. We established a melanoma cell line from a tumor with none of the common driver 
mutations. This cell line demonstrated a signaling profile similar to BRAF-mutants, but lacked 
sensitivity to the BRAF inhibitor vemurafenib. RNA-seq mutation data implicated CRAF R391W as the 
alternative driver mutation of this melanoma. CRAF R391W was homozygous and over expressed. 
These melanoma cells were highly sensitive to CRAF, but not BRAF knockdown. In reconstitution 
experiments, CRAF R391W, but not CRAF WT, transformed NIH3T3 cells in soft-agar colony formation 
assays, increased kinase activity in vitro, induced MAP kinase signaling and conferred vemurafenib 
resistance. MAP kinase inducing activity was dependent on CRAF dimerization. Thus, CRAF is a bona 
fide alternative oncogene for BRAF/NRAS/GNAQ/GNA11 wild type melanomas.
The majority of melanomas exhibit elevated activity of the MAP kinase (MAPK) pathway, which is primarily the 
result of activating mutations in the proteins upstream or within the pathway1. The discovery of BRAF mutations 
in approximately 50% of metastatic melanomas initiated a turning point for this disease with previously very lim-
ited treatment options2. This led to the development and eventual FDA approval of BRAF and MEK inhibitors3–7. 
Occurring in approximately 25% of cases, the second most common driver mutation in melanoma involves the 
NRAS gene8. For this molecular subtype of melanoma no strongly effective targeted treatment has been approved 
and only recently a possible benefit of MEK inhibition has been reported9. For the remaining substantial fraction 
of melanomas the driver oncogenes are still unknown. However, other MAPK pathway activating mutations are 
probable.
CRAF (RAF1) belongs to the same protein family as BRAF and is positioned at the same level of the MAP 
kinase signaling cascade. It has been suggested that CRAF is also involved in other activities independent of 
the MAPK pathway including regulation of effectors such as MST-2 (MAP3K10), ASK-1 (MAP3K5)10 and 
anti-apoptotic factors in mitochondria11. In melanoma, CRAF has been mainly implicated in transducing signals 
downstream of NRAS mutants and as a BRAF dimerization partner in paradoxical signaling12 and vemurafenib 
resistance13.
While BRAF was found to be mutated in 8% of all cancers, CRAF demonstrated a significantly lower mutation 
frequency of 0.7% in cancer cell lines14. Although both BRAF and CRAF are expressed and active in melanoma 
signaling processes, only BRAF shows a high mutation frequency (approximately 50% of melanomas), whereas 
CRAF mutations are rare and so far have not been demonstrated to generate an alternative activated oncogene. 
Explanations for this striking difference have implicated the additional levels of negative regulation acting on 
CRAF, which – unlike BRAF – requires more than one mutation for the activation of an independent high kinase 
activity with MAPK inducing abilities14. Nevertheless, recently, it was found that single amino acid exchanges on 
CRAF can mediate vemurafenib resistance in BRAF V600E mutant cells15. Moreover, even the elevation of CRAF 
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levels has been reported as a potential mechanism of resistance in BRAF mutant melanomas16. However, for both 
resistance mechanisms the in vivo occurrence has not been demonstrated.
Here we report the identification of a natural cancer-associated mutation of the CRAF gene in both the biopsy 
of a nodular metastasis from melanoma and its derived cell line, and provide evidence that the identified CRAF 
R391W mutation causes continuous homodimerization of CRAF, induces high activity of the MAPK pathway 
and exhibits the characteristics of a bona fide melanoma oncogene.
Results
Characterization of the BRAF WT/NRAS WT M375 melanoma cell line. A 69 year old patient 
underwent axillary lymph node resection after the finding of stage III melanoma with nodal metastases. One out 
of seven axillary lymph nodes was involved with melanoma, from which the M375 cell line was established. The 
M375 cell line was found to be negative for BRAF and NRAS mutations by Sanger sequencing. However, growth 
inhibition assays suggested that it had constitutively active MAPK signaling, since it was sensitive (IC50 = 774 nM) 
to the pan-RAF inhibitor (pan-RAFi, Amgen Compd A) and to the MEK inhibitor trametinib (IC50 < 4 nM). 
Expectedly, growth of M375 was not inhibited by the BRAF inhibitor vemurafenib, and unlike some other cell 
lines with wild type BRAF the growth rate of M375 did not paradoxically increase by this drug (Fig. 1A). For 
comparison, the effect of pan-RAFi and the other inhibitors on the growth of four other melanoma cell lines with 
different mutations in the MAPK pathway (c-KIT mutant M230, BRAF mutant M397, BRAF WT/NRAS WT 
PB, and NRAS mutant M311 cell lines), and with a range of sensitivities, are shown in Supplementary Figure 1.
To gauge the activity and pattern of the MAPK pathway response to the inhibitors, M375 and three other mela-
noma cell lines (M230, M397 and PB), were treated with 1 μ M of pan-RAFi, 1 μ M of vemurafenib, or solvent alone 
as the control for 24 h. Interestingly, Western blot analysis indicated that at baseline level, the pattern and levels of 
MAPK pathway activity (p-MEK and p-ERK) in M375 are more similar to BRAF mutant M397 than the other two 
tested BRAF WT/NRAS WT cell lines (Fig. 1B, Supplementary Figure 2A,B). The pan-RAFi blocked phospho-
rylation of p-MEK and p-ERK in both the M375 and M397 cell lines. However, as expected, the BRAF inhibitor 
vemurafenib was only effective in the BRAF mutant M397 (Fig. 1B). Taken together, the pathway inhibition data 
implicated the role of an alternative MAPK pathway activator in driving the oncogenic phenotype of M375.
Identification of CRAF R391W as a candidate melanoma oncogene in the M375 cell line and 
matched patient samples. Considering the high activity of the MAPK pathway in the BRAF WT/NRAS 
WT cell line M375 and its sensitivity to pan-RAFi and MEKi, we hypothesized that in this cell line activity of 
the MAPK pathway is the result of a driving mutation upstream in the MAPK pathway, generating a signaling 
pattern similar to what is seen with BRAF mutants. To investigate this hypothesis, total RNA from M375 and 
the three other melanoma cell lines (M230, M397 and PB) was isolated and subjected to RNA-seq analysis 
(Fig. 1C). This analysis indicated that M375 contains a homozygous A to T mutation at nucleotide 1171 of the 
CRAF gene. This mutation results in an Arg to Trp missense mutation in the CRAF protein (CRAF R391W). 
To determine CRAF RNA levels, RNA-seq data were analyzed by quantifying read counts of this gene using 
HTSeq version 0.5.4. and normalizing them by the DESeq R package. Strikingly, RNA expression of CRAF in 
M375 was at least 10 fold higher than the average CRAF expression in other cell lines (Fig. 1D), which supports 
a strong positive selection pressure on the mutated allele. To confirm presence of this mutation in the original 
tumor and to provide evidence that it is the result of a somatic mutation, Sanger sequencing was performed on 
the genomic DNA samples isolated from M375 cell line, the metastatic lymph node resection, and the matched 
patient’s blood mononuclear cells. Sequencing confirmed the homozygous CRAF A1171T mutation in the cell 
line and the tumor, but no mutation in the blood sample was found. Therefore, CRAF A1171T is a homozy-
gous somatic mutation, which translates to the mutated protein CRAF R391W in the tumor and the cell line 
(Fig. 1E). Western blot analysis confirmed strongly elevated abundance of CRAF protein levels in the M375 cell 
line (Fig. 1F). With this, the results strongly implicate mutated CRAF R391W as a candidate alternative driver 
of oncogenic MAPK signaling.
Role of CRAF R391W in induction of the MAPK pathway and cellular proliferation. To investi-
gate the importance of CRAF R391W in induction of the MAPK pathway and proliferation of the M375 cell line, 
expression of this gene was silenced by a CRAF specific siRNA pool. Highly efficient blockade of CRAF expres-
sion after 72 hours of siRNA transfection was accompanied by a very substantial down regulation of RAF down-
stream factors p-MEK and p-ERK (Fig. 2A). Moreover, knockdown of CRAF resulted in a significant growth 
inhibition of M375 cells. The inhibition of growth was dose-dependent on the amount of CRAF siRNA. Greater 
than 70% growth inhibition could be achieved by 8 nM of CRAF siRNA, while non-targeted siRNA showed no 
effect on the growth of the M375 cell line (Fig. 2B). For comparison, the same assays were performed with BRAF 
siRNA in the M375 cell line, which was verified to significantly down regulate the BRAF protein. However, no 
decrease in activity of the MAPK pathway or proliferation of this cell line was observed (Fig. 2C,D). Similarly, the 
growth of this cell line was not affected by the BRAF inhibitor vemurafenib (Fig. 1A). In contrast, CRAF knock-
down in a panel of CRAF wild type cell lines (the NRAS mutant cell line M207, the vemurafenib resistant BRAF 
mutant cell line M233, and the vemurafenib sensitive BRAF mutant cell line M238) had little to no effect on pro-
liferation (Fig. 2E–G). These results indicate that M375 is not strongly dependent on BRAF and that expression of 
mutated CRAF is critical for activation of the MAPK pathway and proliferation of this cell line.
CRAF R391W expression reconstitutes MAP-kinase activation dependent on CRAF dimerization. 
Next we asked whether the CRAF R391W mutation could induce down-stream MAP kinase pathway activation. 
For this, we expressed wild type CRAF, CRAF R391W, BRAF V600E, or the empty vector in 293T cells. CRAF 
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R391W strongly induced the MAP-kinase pathway as indicated by activating MEK and ERK phosphorylation 
(Fig. 3A). The activation level induced by CRAF R391W and BRAF V600E was comparable, whereas CRAF WT 
had no activating effect. Of note, MAP kinase pathway activation observed for CRAF R391W expression was not 
dependent on external stimulation by serum components (Fig. 3B).
The R391W mutation is located in the center of the α C-helix of the CRAF kinase domain (Fig. 3C). Movement 
of the α C-helix is involved in kinase activation17,18. To test whether MAP kinase pathway activation by CRAF 
R391W is due to its higher enzymatic activity, we conducted a kinase assay with GST-MEK as the substrate 
(Fig. 3D). Purified CRAF R391W showed a highly elevated kinase activity compared to CRAF WT. In this exper-
iment, BRAFV600E demonstrated an even higher elevated activity towards phosphorylating MEK. Further 
Figure 1. Identification of CRAF R391W as a candidate melanoma oncogene in a BRAF WT/NRAS 
WT cell line (M375) and matched patient sample. (A) Growth inhibition assay demonstrates sensitivity 
of the BRAF/NRAS wild type cell line M375 to pan-RAF inhibitor (PRi) and MEK inhibitor (MEKi) and 
its resistance to the BRAF inhibitor vemurafenib. M375 was treated with serial dilutions of these drugs in 
duplicate. MEKi concentration was 1/10 of the PRi and vemurafenib concentration for each dilution. The assay 
was repeated twice. Error bars indicate the standard error. (B) MAP-kinase signaling and inhibitor treatment 
response of CRAF mutant M375 cells is reminiscent of BRAF mutated cells except for lack of vemurafenib 
sensitivity. Western blot assay was performed on CRAF mutant M375, c-KIT mutant M230, BRAF mutant 
M397 and NRAS/BRAF wild type PB cell lines to analyze their MAPK pathway activities at basal levels or after 
treatment with 1.0 μ M of PRi or vemurafenib for 24 hours. Densitometry results for these blots are shown in 
Supplementary Figure 2. (C) RNA-seq analysis of M375 reveals a homozygous CRAF A1171T mutation (CRAF 
R391W). RNA-seq analysis was performed for the M375, M230 (c-KIT mutant), M397 (BRAF mutant), and PB 
(BRAF WT/NRAS WT) cell lines. For discovery of the CRAF R391W mutation all mutations detected in the 
sequencing data were filtered for potentially damaging mutations in the MAP kinase pathway (see methods). 
The table shows the detected mutations in the common melanoma oncogenes and CRAF for the four cell lines. 
(D) mRNA expression of CRAF in the four cell lines as determined by RNA-seq analysis. M375 shows > 10x 
higher expression of CRAF (R391W). (E) CRAF A1171T/R391W mutation in M375 and its corresponding 
tumor is the result of a somatic mutation. Sanger sequencing was performed on the genomic DNA samples 
isolated from M375 cell line, its corresponding tumor and matched blood of the patient. Sequencing confirmed 
the presence of CRAF A1171T mutation in the tumor, its derived cell line (M375), but not in the blood of the 
patient. (F) Western blot analysis shows strongly elevated abundance of CRAF protein levels in the CRAF 
mutated melanoma cell line M375 in comparison with 3 other melanoma cell lines.
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experiments would be required to quantitatively determine if BRAFV600E or CRAF R391W has an inherently 
stronger ability to induce the MAPK pathway.
In most settings activation and signaling of RAF proteins depends on their dimerization state13,19,20. It has 
been suggested that the α C-helix – with its centrally located R391 residue – is important for RAF protein dimer-
ization18,21,22. We tested combinations of WT and mutant CRAF R391W for homo-dimerization and found that 
the R391W mutation induces homo-dimerization of CRAF, in comparison to the wild type case. To a lesser but 
detectable level, the R391W mutation also induces mutant CRAF:wild type CRAF hetero-dimerization (Fig. 3E, 
Supplementary Figure 3A,B).
To test, whether homo-dimerization is critical for CRAF R391W activity, we tested the effect of the CRAF 
R401H dimerization mutation. CRAF R401H has been reported to block functional dimerization of CRAF 
(Supplementary Figure 4)19,20,22. Of note, the R401H mutation does not fully block the physical association of two 
monomers, but rather is critical for the blocking of dimerization-dependent transactivation of RAF proteins20,22,23. 
Strikingly, combining R401H with CRAF R391W resulted in a nearly complete loss of down-stream MAP-kinase 
activation – reverting it back to the substantially reduced activity level of CRAF WT (Fig. 3F). This demonstrates 
that a single mutation in CRAF (R391W) leads to strongly induced kinase and pathway activity dependent on the 
formation of functional (trans-activating) dimers.
Figure 2. The M375 cell line is dependent on mutated CRAF R391W for MAPK pathway activity and 
proliferation. (A) Knockdown of CRAF inhibits the MAPK pathway in M375. Western blot analysis of the 
MAPK pathway activity in M375 cell line performed 72 hours after transfection with the non-target (siCon) 
or CRAF specific siRNA pool. (B) Knockdown of CRAF causes a significant growth inhibition in the M375 
cell line. The M375 cell line was transfected in a ½ serial dilution with CRAF siRNA or non-target siRNA 
(siCon) in triplicates. For transfection of siRNAs at all concentrations, a constant amount of Lipofectamine 
RNAiMAX (0.2%) was used. The data points marked by an asterisk correspond to the control with no siRNA 
and lipofectamine. (C) BRAF knockdown in M375 cells does not affect downstream MAP-kinase signaling. 
Western blot to analyze the effect of BRAF knockdown on activity of the MAPK pathway activity in the CRAF 
mutant M375 cell line. The assay was performed 72 hours after transfection with the non-target (siCon) or 
BRAF specific siRNA pool. (D) BRAF knockdown does not inhibit the growth in M375 cells. The assay was 
performed as describe above. (E–G) CRAF knockdown does not cause growth inhibition in a small panel of 
CRAF wild type, NRAS or BRAF mutant melanoma cell lines. Growth assays performed on the NRAS mutant 
cell line M207, vemurafenib resistant BRAF mutant cell line M233, and vemurafenib sensitive BRAF mutant cell 
line M238. Error bars indicate the standard error.
www.nature.com/scientificreports/
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CRAF R391W is transforming and can functionally replace BRAF V600E and induce resistance 
to a BRAF inhibitor. After confirming the activating effect of CRAF R391W on the signaling level, we asked, 
whether CRAF R391W expression also induces phenotypic oncogenic alterations. First, we tested whether CRAF 
R391W is active in a 3T3 soft-agar transformation assay and supports anchorage-independent growth (Fig. 4A). 
CRAF R391W was transforming in this assay and induced strikingly and significantly more soft-agar colonies 
than cells carrying the control vector.
Next, we tested, whether exogenous expression of CRAF R391W can functionally replace BRAF V600E in a 
melanoma cell line. The vemurafenib sensitive BRAF mutant cell line M238 was transduced with an empty ret-
rovector, CRAF WT and CRAF R391W and selected for stable transduction. From each one of these conditions 
a pool of stably transduced cells was subjected to treatment with 0.1 to 5.0 μ M of the BRAFi vemurafenib or the 
Figure 3. Engineered CRAF R391W expression reconstitutes MAP-kinase activation dependent on CRAF 
dimerization. (A) CRAF R391W activates downstream MAP-kinase signaling. An empty vector control, CRAF 
R391W, CRAF wild type (WT), and BRAF V600E were transiently expressed in 293T cells and downstream 
MAP-kinase pathway activation was measured by Western blot after 48 h (p-ERK T202/Y204 and p-MEK 
S217/221). The N-terminally HA-tagged genes (pDS_HA vector) were transfected in increasing amounts (2, 
4, 8 μ g DNA per one well of a 6-well plate; 2 and 4 μ g for BRAF V600E; as indicated by the gradient triangles). 
Expression of the transfected genes was tested with an anti-HA antibody. The relatively faint lower band in 
the HA-BRAF lane, which runs slightly faster than the HA-CRAF protein, appears to be a minor degrative 
product of the exogenously produced HA-BRAF protein. (B) MAP-kinase pathway activation by CRAF R391W 
does not depend on serum-derived growth factors. Experiment in (A) was repeated in the absence (w/o) and 
presence (w/) of serum. (C) Arg391 is located in the α C-helix of CRAF. Structure 3OMV from PDB database 
visualized with SwissPDB-Viewer48,49. (D) CRAF R391W shows increased kinase activity. The empty control 
vector (N-terminal HA-tag, pDS_HA, 8 μ g DNA per 6cm plate), CRAF R391W (4 and 8 μ g DNA), CRAF 
wild type (WT, 4 and 8 μ g DNA), and BRAF V600E (4 μ g DNA) were transiently transfected into 293T cells. 
Anti-HA immunoprecipitation and in vitro kinase assay were performed with GST-MEK as the substrate. 
Phosphorylation of GST-MEK by the precipitated kinases was detected by Western blot. (E) CRAF R391W 
shows increased homo-dimerization. HA- and Myc-tagged constructs of CRAF R391W (RW), CRAF wild 
type (WT), and the empty HA-vector were transiently transfected into 293T cells. Expression was checked by 
Western blot (input). The HA-tag was immuno-precipitated and co-precipitation of Myc-tagged proteins was 
checked by Western blot (HA-IP). (F) CRAF R391W activity depends on its dimerization state. The previously 
described R401H mutation was introduced into CRAF R391W to interfere with functional dimer formation. 
Downstream MAP-kinase activation of the different constructs was tested as in (A) (2 or 4 μ g DNA transfected, 
0.5, 1, 2, or 4 μ g DNA of BRAF V600E).
www.nature.com/scientificreports/
6Scientific RepoRts | 6:27454 | DOI: 10.1038/srep27454
pan-RAFi for 24 hours. Analysis of the MAPK pathway indicated that CRAF R391W could functionally replace 
BRAF V600E as the CRAF R391W expressing M238 cell line did not show any reduction in p-MEK and p-ERK 
levels upon treatment with vemurafenib. On the other hand, in the M238 CRAF R391W cell line the MAPK path-
way was inhibited by pan-RAFi to a degree similar to the original CRAF mutant cell line M375 (Fig. 1B). Both 
M238 control and M238 CRAF WT showed inhibition of the MAPK pathway by vemurafenib and pan-RAFi 
(Fig. 4B).
The growth inhibition response of these three cell lines reflected the response pattern of the MAPK pathway 
(Fig. 4C–E). Both the M238 control and M238 CRAF WT cell lines were sensitive to vemurafenib and pan-RAFi. 
This shows their dependence on mutated BRAF as the oncogenic driver and the inability of CRAF WT to com-
pensate for mutated BRAF. On the contrary, the M238 CRAF R391W cell line was substantially resistant to 
vemurafenib, but still demonstrated growth inhibition by pan-RAFi. Upon treatment with these inhibitors, cell 
cycle analysis of M238 engineered cell lines showed patterns consistent with cell cycle arrest being a substantial 
component of the observed growth inhibition results (Supplementary Figure 5A). Measuring cleaved PARP also 
indicated that exogenous expression of CRAF R391W prevented induction of apoptosis by vemurafenib in M238 
CRAF R391W cells while these cells showed significant apoptosis upon treatment with pan-RAFi and MEKi 
(Supplementary Figure 5B). These results demonstrate that in a melanoma cell line context, CRAF R391W can 
assume an oncogenic driver role and compensate for the loss of the oncogenic function of mutated BRAF.
The previously described CRAF E478K mutation is less activating and requires an upstream 
mutation for full activity. After establishing CRAF R391W as a driver oncogene for the M375 cell line and 
original tumor, we asked how this mutation compares to CRAF E478K. CRAF E478K has been previously identi-
fied as an activating and potential oncogenic mutation for melanoma8 and colorectal carcinoma14.
We expressed CRAF R391W, CRAF E478K, and controls in 293T cells and analyzed downstream MAP kinase 
activation by Western blot (Fig. 5A). While CRAF E478K showed increased activation compared to CRAF WT, 
its inducing effect was notably lower than the level observed for CRAF R391W. This is in agreement with previous 
reports, which concluded that CRAF E478K acts as an oncogene in conjunction with other activating mutations 
Figure 4. CRAF R391W is transforming and can functionally replace BRAF V600E in BRAFi-treated 
melanoma cells. (A) CRAF R391W induces anchorage independent growth in NIH3T3 cells soft-agar 
transformation assay. Bar = 250 μ m, t-test p-value < 0.05. (B) Exogenous expression of CRAF R391W in 
the vemurafenib sensitive BRAF mutant M238 cell lines abrogates the inhibitory effect of vemurafenib on 
the MAPK pathway activity. Stable M238 cell lines expressing wild type CRAF (WT), CRAF R391W, or the 
empty vector (pDS-FB-hyg) were established, treated with increasing concentrations of pan-RAF inhibitor 
(PRi), vemurafenib (Vem), or the DMSO control for 24 h, and analyzed for downstream MAP-kinase pathway 
activation by Western blot. (C–E) Exogenous expression of CRAF R391W mediates vemurafenib resistance in 
BRAF mutant M238 cells. Growth inhibition assays performed on the stable M238 cell lines: M238 control (C),  
M238 CRAF WT (D) and M238 CRAF R391W (E). Cells were treated with serial dilutions of PRi or 
vemurafenib for 5 days. The assay was performed at least twice. Error bars indicate the standard error.
www.nature.com/scientificreports/
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such as an upstream RAS mutation14. We were able to confirm that CRAF E478K can work in conjunction with a 
KRAS mutant (V12) to activate the MAP kinase pathway, whereas CRAF R391W without oncogenic RAS already 
induces strong pathway activity (Fig. 5B). While we observed that MAP kinase pathway activation by CRAF 
R391W can occur in the absence of serum (Fig. 3B), it remains to be determined if participation of wildtype RAS 
activation is required, or if, as is the case for BRAFV600E24, signaling activation by CRAF R391W is completely 
independent of upstream RAS involvement. In sum, CRAF R391W represents an oncogenic mutation in mela-
noma that independent of oncogenic RAS can drive a high level of downstream MAP-kinase pathway activation 
and support oncogenic transformation.
Discussion
In this study, we identified a CRAF R391W missense mutation in a melanoma metastasis biopsy and its derived 
cell line. This CRAF mutation shows the critical aspects of an oncogenic driver mutation: homozygosity and 
highly amplified expression of this locus indicates strong positive selection pressure25; the derived melanoma cell 
line is strictly dependent on CRAF (R391W) expression for activity of MAPK signaling and proliferation; exog-
enous CRAF R391W expression strongly enhances kinase activity, homodimerization and induces downstream 
MAP kinase signaling; and CRAF R391W induces anchorage independent growth and can functionally replace 
BRAF V600E in a melanoma cell line.
The kinase family members CRAF and BRAF both activate MAP kinase signaling and are considered onco-
genes2,26. However, CRAF mutations are much less frequent in human cancers. For example, a study found BRAF 
mutations in 8% of cancer cell lines, whereas CRAF was only mutated in 0.7% of the tested cell lines14. In a com-
pendium of datasets from recent cancer sequencing projects, 0.6% of samples showed a CRAF mutation (up to 
4% for a single cancer type) and 4.3% a BRAF mutation (up to 58% for a single cancer type) (as of Nov. 2013)27. 
The TCGA project with 228 melanoma samples detected BRAF mutations in 51% and CRAF mutations in 4% 
of the melanoma cases. Upon our search, two samples in this database showed a CRAF mutation at position 
R391: one melanoma with R391S mutation (TCGA-EE-A20C, concurrent with a NRAS Q61R mutation) and one 
renal papillary cell carcinoma with R391W mutation (TCGA-B3-3925, without RAS mutation). In addition, the 
corresponding amino acid in BRAF (K499E/N) has been found mutated in the congenital cardiofaciocutaneous 
syndrome 1 (CFC1) disorder28–30. Strikingly, this syndrome is associated with MAP kinase pathway dysregulation 
and BRAF K499E has been shown to activate the pathway28,29.
Several studies have confirmed that single amino acid substitutions can activate CRAF, convert CRAF into a 
transforming oncogenic kinase, and mediate BRAF inhibitor resistance14,15,31–34. Our study extends this work by 
demonstrating that mutated CRAF can be a potent alternative oncogene for malignant melanoma. The question 
arises why BRAF mutations are much more frequent than CRAF mutations. Previously, it has been suggested that 
tighter regulation of CRAF by its inhibitory N-region suppresses activity of CRAF mutations below their trans-
formation threshold14. In the prior work, CRAF E478K was presented as an example for a mutation that is not 
Figure 5. Higher endogenous activity of CRAF R391W than the previously described less active and 
upstream mutation-dependent CRAF E478K. (A) CRAF E478K activates downstream MAP-kinase 
signaling to a lesser extent than CRAF R391W. An empty vector control, CRAF R391W, CRAF E478K, CRAF 
wild type (WT), and BRAF V600E were transiently expressed in 293T cells and downstream MAP-kinase 
pathway activation was measured by Western blot after 48 h (p-ERK T202/Y204 and p-MEK S217/221). The 
N-terminally Myc-tagged genes (pDS_Myc vector) were transfected in two amounts (2 and 4 μ g DNA per one 
well of 6-well plate; triangles). Expression of the transfected genes was tested with an anti-Myc antibody. 
(B) Co-expression of CRAF E478K and mutant KRAS V12 enhances its activation of downstream MAP-kinase 
signaling. The control and CRAF mutant plasmids (pDS_Myc) were co-transfected with KRAS V12 or its empty 
vector (pDS-neo) in two different amounts: 1 μ g or 2 μ g of each plasmid. Downstream MAP-kinase pathway 
activation was measured by Western blot after 48 h as above.
www.nature.com/scientificreports/
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sufficiently active as an oncogene due to inhibitory regulation of the N-region. In our comparison, CRAF R391W 
shows substantially stronger induction of the MAP kinase pathway than CRAF E478K (Fig. 5), and demonstrates 
an activating effect comparable to BRAF V600E (Fig. 3). Thus, mutant CRAF can act as a potent oncogene and 
alternative explanations need to be examined for the reduced observed mutational occurrence of CRAF com-
pared to BRAF. For example, it is possible that the mutation rates for BRAF and CRAF are different or CRAF is 
more constrained by its regulatory network14. In addition, the possibility remains that some of the previous stud-
ies have missed oncogenic genetic events that might activate CRAF through structural variations of the inhibitory 
N-terminus due to the employed sequencing and analysis approaches26,35,36.
How does the R391W mutation activate CRAF and downstream MAP kinase signaling? Arg-391 is centrally 
located in the α C-helix of the kinase domain of CRAF (Fig. 3C). Since movement of the α C-helix is involved in 
kinase activation17,18, this mutation could directly stabilize the active kinase conformation. However, it has also 
been suggested that the α C-helix is important for RAF dimerization18,21,22, which in most settings is crucial for 
its activity13,19,20. We found that both CRAF kinase activity and homo-dimerization are induced by R391W and – 
unlike BRAF V600E37 – this activity depends on functional dimerization (Fig. 3).
Melanoma has been characterized as a cancer that is mainly driven by MAP kinase pathway dysregulation1. At 
the onset of our study we noticed the striking similarity of the signaling pattern of the M375 cell line and BRAF 
V600E cell lines (Fig. 1). This led to the discovery of CRAF R391W as an alternative oncogene that drives the 
MAP kinase pathway. This finding further underscores the importance of MAP kinase signaling for melanoma. 
Importantly, this finding suggests that MAP kinase pathway inhibition can – in principle –constitute a viable 
treatment option for a subset of BRAF/NRAS wild type melanomas. For example, whereas the M375 cell line is 
resistant to BRAF inhibition by vemurafenib, it is sensitive both to pan-RAF and MEK inhibition (Fig. 1).
In conclusion, we have discovered and characterized CRAF R391W as a novel oncogene for BRAF/NRAS wild 
type melanomas. This is the first report of CRAF as a bona fide oncogene in melanoma and adds to the reports of 
oncogenic CRAF variants in other cancers36.
Materials and Methods
Reagents and Cell Lines. Vemurafenib and trametinib were purchased from Selleck Chemicals (Houston, 
TX) and the pan-RAF inhibitor (pan-RAFi, Amgen Compd A38) was obtained from Amgen (Thousand Oaks, 
CA) under a materials transfer agreement (MTA). Human melanoma cell lines used in this study were established 
from patient’s biopsies under UCLA IRB approval #11-003254. Maintenance and mycoplasma testing of the cell 
lines were performed as it was described before39.
RNA-seq analysis & DNA sequencing. Presence of mutations in the genes of interest were investigated 
by Sanger sequencing, OncoMap 3, Iontrone39,40 or RNA-seq. For RNA-seq, cells were harvested and subjected to 
RNA isolation by RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer instruction. Total RNA sam-
ples were converted into cDNA libraries using a modification to the Illumina TruSeq RNA Sample Preparation 
Kit v2 to impart strand specificity. cDNA was then amplified by PCR. Final cDNA libraries were analyzed for 
size distribution using an Agilent Bioanalyzer, quantitated by qPCR and normalized to a concentration of 2 nM 
prior to submission to Expression Analysis, Inc. (Durham, NC) for 50 bp paired end sequencing on the Illumina 
platform. Read mapping was performed using TopHat version 2.0.9 with the NCBI Build 37 reference genome41. 
Read counts per gene were quantified using HTSeq version 0.5.4 and normalized using the DESeq R package42. 
Variant calling was performed using the Genome Analysis Toolkit version 2.7 and annotated using Annovar43,44. 
To analyze the CRAF mutation, DNA was isolated from the patient tumor sample, the patient’s blood, and the 
patient-derived melanoma cell line M375. For this, the “DNeasy Blood and Tissue Kit” (Qiagen, Valencia, CA) 
was used. The patient FFPE tumor sample was subjected to xylene/ethanol treatment before DNA isolation. The 
relevant region of the CRAF gene was amplified with the Phusion High-Fidelity DNA Polymerase (NEB, Ipswich, 
MA) (forward primer: CTA ACT GTA GCG ATA GCA GTT AAC C; reverse primer: GCA CAG TCC ACT 
AAC TCT ACA GTC) and submitted for sequencing at the UCLA sequencing core facility (sequencing primer: 
TGGATAAATGATTCACTGTATCTTCC).
Growth inhibition and transformation assays. Pharmacological growth inhibition assays were per-
formed as previously described39. Each condition was in duplicate and assays were repeated at least twice. For 
siRNA experiments, knockdown of the target genes by siRNA was performed as it was described before39. In 
brief, cell lines were transfected with 32 nM of specific siRNA for either CRAF or BRAF or no target siRNAs 
(Dharmacon, Lafayette, CO) by using 0.2% of Lipofectamine® RNAiMAX (Life technologies, Carlsbad, CA). 
Knockdown growth inhibition assays were performed by transfecting the cell lines with the ½ serial dilutions of the 
target siRNA or non-targets siRNA (siCon) in triplicates. The highest concentration of each siRNA was 32 nM. For 
transfection of siRNAs at all concentrations, a constant amount of Lipofectamine® RNAiMAX (0.2%) was used.
NIH3T3 cells stably transfected with CRAF R391W or the empty retroviral vector (pDS-FB-hyg) and were 
plated in soft-agar plates. A 0.8% (w/v) agarose base layer with 0.5x DMEM + 10% FBS + antibiotics media was 
prepared in 6cm plates. 1 × 105 cells were plated on the base layer in 0.35% agarose and 0.75x DMEM + 10% 
FBS + antibiotics. The assay was performed in triplicates. The plates were supplemented with fresh media every 
3–5 days. Colonies were counted and microscopic images taken after 24 days.
Inhibitor treatment and Western Blot experiments. Western blotting was performed as previously 
described39. The conditions and duration of treatments of the cells before protein isolation are described in the 
text and the figure legends. Primary antibodies included p-ERK Thr204/205, ERK, p-MEK Ser217/221, MEK, 
anti-HA (clone C29F4) and GAPDH (all from Cell Signaling Technology, Danvers, MA), BRAF (H-145) and 
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CRAF (E-10) (both from Santa Cruz biotechnology, Santa Cruz, CA), anti-MYC and anti-actin (Sigma Aldrich, 
St. Louis, MO). Secondary antibodies were HRP conjugates (Santa Cruz biotechnology, Santa Cruz, CA). 
Densitometry of bands was performed by using ImageJ program.
Cell Cycle Analysis and Apoptosis. Cell lines were treated with DMSO, 1.0 μ M of vemurafenib, 1.0 μ M of 
pan-RAFi, or 25 nM of MEKi for 48 hours before the harvest, fixation and DAPI staining for cell cycle analysis45. 
For apoptosis assay, all treatments and preparations were similar to the cell cycle analysis. Cells were stained for 
cleaved poly [ADP-ribose] polymerase (PARP) by anti–PARP-Alexafluor700 (clone F21–852; BD Biosciences). 
LSRII (BD Biosciences) flow cytometry machine was used for both cell cycle analysis and cleaved PARP positive 
cell detection.
CRAF/BRAF expression constructs. A CRAF plasmid (pDONR223-CRAF), KRAS V12 plasmid 
(pDONR223-K-RAS V12), and BRAF V600E plasmid (pBabe-Puro-BRAF-V600E) were obtained from 
Addgene (Cambridge, MA). BRAF V600E was PCR amplified and cloned into a Gateway-system entry plasmid 
(pDonr207) (life, Carlsbad, CA). CRAF was transferred into the pDonr207 plasmid and a stop codon was added 
by a similar procedure. The following CRAF mutations were generated by overlap extension PCR and re-cloning 
into the pDonr207 plasmid by BP recombination: CRAF R391W, CRAF R391W R401H, and CRAF E478K. These 
entry clones were transferred into the following destination vectors: pDS_MYC and pDS_HA (n-terminal epitope 
tags; Alliance for Cellular Signaling), pDS-FB-hyg (retroviral expression vector, Alliance for Cellular Signaling), 
and pCEMM-CTAP-GWY (retroviral expression vector; GFP marker; tag not expressed due to presence of stop 
codon)46. Retroviral particles were produced as described previously47. Virus supernatants were harvested after 
48 h and filtered. For the transduction, the cells were incubated with the viral supernatant and 4 μ g/ml polybrene.
MAP-kinase pathway activation by CRAF mutants. For the analysis of downstream MAP-kinase 
pathway activation by CRAF/BRAF constructs, 293T cells were transfected with the expression plasmids using 
Lipofectamine 2000 (Life, Carlsbad CA). Cells were cultured in DMEM + 10% FBS + antibiotics except when 
explicitly stated that serum (FBS) was omitted. Forty eight hours after transfection the cells were lysed with 
mRIPA buffer (150 mM NaCl, 1% (v/v) NP-40, 0.25% (w/v) Na-deoxycholate, 1 mM EDTA, 50 mM Tris/HCl, 
pH = 7.4) with proteinase (1 mM PMSF, 20 μ g/ml leupeptin, 20 μ g/ml aprotinin) and phosphatase inhibitors 
(10 mM NaF, 10 mM beta-glycerophosphate, 10 mM Na-pyrophosphate, and 1 mM Na3VO4). Western blots 
were performed using a standard protocol, infrared secondary antibodies were used (IRDye 680 goat anti-rabbit 
and IRDye 800CW goat anti-mouse, LI-COR, Lincoln, NE), and the blots scanned with a LI-COR scanner 
(LI-COR Lincoln, NE).
Kinase activity assay. 293T cells were transfected with the empty HA-tag expression plasmid (pDS_HA 
vector) or HA-tagged constructs of CRAF R391W, CRAF wild type, and BRAF V600E using Lipofectamine 2000 
(Life, Carlsbad, CA). Forty eight hours after transfection the cells were lysed in lysis buffer (125 mM NaCl, 0.2% 
(v/v) NP-40, 50 mM Tris/HCl, pH = 7.5, 1.5 mM MgCl2, 5% (v/v) glycerol and proteinase and phosphatase inhib-
itors) with two freeze-thaw cycles in N2(l). The HA-tagged proteins were immunoprecipitated with anti-HA mag-
netic beads (Pierce, Thermo Fisher, Rockford, IL) for 2 h at 4 °C. The immunoprecipitates were washed thrice with 
lysis buffer. The in vitro kinase assay was conducted using the B-Raf Assay Kit (EMD Millipore, Billerica, MA). 
Briefly, 20 ul Mg/ATP cocktail, 1 μ g GST-MEK1 (inactive), and 22 ul ADBI buffer were added to the beads and 
incubated for 30 min at 30 °C. The samples were boiled in SDS sample buffer and analyzed by LI-COR Western 
blot as described above.
Co-immunoprecipitation. 293T cells were co-transfected with pairs of HA- and MYC-tagged constructs 
(pDS_HA and pDS_MYC vector) of CRAF wild type, CRAF R391W, or CRAF R391W R401H (or the empty 
vector) by using Lipofectamine 2000 (Life, Carlsbad, CA). Forty eight hours after transfection the cells were lysed 
in lysis buffer (as described in kinase assay). The HA-tagged proteins were immunoprecipitated with anti-HA 
magnetic beads (Pierce, Thermo Fisher, Rockford, IL) overnight at 4 °C. The immunoprecipitates were washed 
thrice with lysis buffer. Co-immunoprecipitates were eluted with 0.1 M glycine, pH = 2.0 and neutralized with 1 M 
Tris/HCl, pH = 8.5. The input fractions and elutes were analyzed by Western Blot as described above.
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